Clinical trial
A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer
NCT02653313 is registered in ClinicalTrials.gov with Oryx GmbH & Co. KG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer
- Lead sponsor
- Oryx GmbH & Co. KG
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- December 31, 2015
- Completion date
- May 31, 2018
- Enrollment
- 7 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.